# A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

> **NCT05132413** · PHASE3 · UNKNOWN · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 561 (estimated)

## Conditions studied

- Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer

## Interventions

- **DRUG:** SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab
- **DRUG:** Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin
- **DRUG:** Placebo 1 + Placebo 2 +Pemetrexed Disodium + cisplatin/carboplatin

## Key facts

- **NCT ID:** NCT05132413
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12-30
- **Primary completion:** 2024-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 561 (ESTIMATED)
- **Last updated:** 2021-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05132413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05132413, "A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05132413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*